Simplifying Testing, Amplifying Access

We are advancing the use of saliva-based testing as a readily-deployable, sensitive, patient-friendly option that increases access to affordable and equitable infectious disease testing.

Since
0
Labs Designated
0 +
Tests Administered
0 mil+

Save the date

SalivaDirect, Inc. is thrilled to announce that our annual conference for 2025 will be held virtually! Mark your calendars for June 3-6 to hear from top experts in diagnostics on a GLOBAL scale.

Scalable solutions for global health: the SalivaDirect model

Check out Frontiers’ latest perspective article on the SalivaDirect Model! Focused on scalable solutions for global health, this highlights the challenges faced during the COVID-19 pandemic and how innovative testing methods can improve our response to future health crises. 

Giving Tuesday

The countdown to #GivingTuesday has begun! Your contribution to our “Shape the Future of Diagnostics” campaign will help fund initiatives like our mobile lab, improving testing access in underserved communities.

News & Updates

November 16, 2024

Where Activism Meets Science: Spotlight on Russell Thomas

July 12, 2024

Mobile Lab Helps Yale Pathology Establish Relationships, Build Trust With Community

July 11, 2024

Saliva-based tests offer an alternative to nasal swabbing

January 27, 2024

New partnership between CT, Yale to expand saliva-based COVID testing at 2 New Haven locations

April 24, 2023

High-Tech Mobile Lab-in-a-Van Will Bring Needed Testing to Underserved Communities

August 17, 2020

Saliva-Based COVID-19 Test Developed by Yale Scientists Authorized for Emergency Use by FDA

Stay up to date.

Subscribe to the SalivaDirect Newsletter.

The SalivaDirect test is a cutting-edge, non-invasive COVID-19 diagnostic test that detects SARS-CoV-2 RNA from saliva samples. 

The SalivaDirect test for COVID-19 is:

Non-Invasive and Self-collectible

Saliva collection is non-invasive, reducing patient aversion to testing. It is readily self-collected, which can reduce the risk of viral transmission to healthcare workers.

Flexible and Scalable

The reagent-flexible and instrument-flexible nature of the SalivaDirect protocol allows for labs to use their existing suppliers, reducing the barrier to entry for labs.

Cost-efficient

Our test does not require swabs or preservative media in saliva collection devices, reducing the cost of the test kit itself. Additionally, utilizing a nucleic acid extraction-free approach reduces the cost of reagents, labor, and improves your laboratory’s turnaround time.

Authorized for Emergency Use by the FDA

The SalivaDirect protocol for SARS-CoV-2 has been authorized for Emergency Use by the U.S. Food and Drug Administration, ensuring it meets the agency’s rigorous performance standards for in vitro diagnostics. It has additionally been independently validated in 15+ countries across the globe. We anticipate a submission for De Novo authorization from the U.S. Food and Drug Administration in 2025.

Our Funding Partners